Last reviewed · How we verify
OMEZ 40
Omeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
Omeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | OMEZ 40 |
|---|---|
| Also known as | OMEPRAZOLE 40MG |
| Sponsor | Dr. Reddy's Laboratories Limited |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Omeprazole is a proton pump inhibitor (PPI) that irreversibly binds to and inactivates the H+/K+-ATPase enzyme in the gastric mucosa. This blocks the final step of gastric acid production, significantly reducing intragastric acidity. It is used to treat acid-related disorders by maintaining elevated gastric pH.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Constipation
Key clinical trials
- The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients (PHASE3)
- Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OMEZ 40 CI brief — competitive landscape report
- OMEZ 40 updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI